Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,120.00
-160.00 (-1.72%)
At close: Feb 27, 2026

Vaxcell-Bio Therapeutics Revenue

In the year 2024, Vaxcell-Bio Therapeutics had annual revenue of 1.90B KRW with 13,737.28% growth. Vaxcell-Bio Therapeutics had revenue of 921.53M in the quarter ending December 31, 2024, with 6,615.06% growth.

Revenue
1.90B
Revenue Growth
+13,737.28%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
212.11B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20241.90B1.89B13,737.28%
Dec 31, 202313.72M--
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020---
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
EASY BIO,Inc.465.24B
Bioneer320.69B
Macrogen179.98B
JETEMA,75.55B
HLB Therapeutics63.25B
Anterogen.Co.,Ltd.7.32B
ENCell5.91B
Genexine5.81B
Revenue Rankings